Search Results - "van den Berkmortel, F"

Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice by Creemers, S. G., Van Santvoort, B., van den Berkmortel, F. W. P. J., Kiemeney, L. A., van Oort, I. M., Aben, K. K. H., Hamberg, P.

“…Background The recommended treatment for a subset of patients with metastatic prostate cancer (mPC) changed from androgen deprivation therapy (ADT) to…”
Get full text

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer by Vriens, B. E. P. J., Vriens, I. J. H., Aarts, M. J. B., van Gastel, S. M., van den Berkmortel, F. W. P. J., Smilde, T. J., van Warmerdam, L. J. C., van Spronsen, D. J., Peer, P. G. M., de Boer, M., Tjan-Heijnen, V. C. G.

“…Purpose The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of…”
Get full text

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial by Mulder, E E A P, de Joode, K, Litière, S, Ten Tije, A J, Suijkerbuijk, K P M, Boers-Sonderen, M J, Hospers, G A P, de Groot, J W B, van den Eertwegh, A J M, Aarts, M J B, Piersma, D, van Rijn, R S, Kapiteijn, E, Vreugdenhil, G, van den Berkmortel, F W P J, Hoop, E Oomen-de, Franken, M G, Ryll, B, Rutkowski, P, Sleijfer, S, Haanen, J B A G, van der Veldt, A A M

“…The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients…”
Get full text

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol by Janssen, J C, van Dijk, B, de Joode, K, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, van den Eertwegh, A J M, de Groot, J W B, Jalving, M, de Jonge, M J A, Joosse, A, Kapiteijn, E, Kamphuis-Huismans, A M, Naipal, K A T, Piersma, D, Rikhof, B, Westgeest, H M, Vreugdenhil, G, Oomen-de Hoop, E, Mulder, E E A P, van der Veldt, Astrid A M

“…Patients with irresectable stage III or metastatic melanoma presenting with poor prognostic factors are usually treated with a combination of immune checkpoint…”
Get full text

Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort by Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., Berkmortel, F. W. P. J., Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., Rijn, R. S., Boer, A. M. Stevense‐den, Veldt, A. A. M., Vreugdenhil, G., Boers‐Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., Thienen, J. V., Haanen, J. B. A. G.

“…Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long‐term) benefit from…”
Get full text

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs by Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., Uyl-de Groot, C.A.

“…The objective of this study was to evaluate trends in survival and health care costs in metastatic melanoma in the era of targeted and immunotherapeutic drugs…”
Get full text

A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry by Knapen, L.M., Geurts, S.M.E., Ibragimova, K.I.E., Croes, S., Vriens, B.E.P.J., van den Berkmortel, F.W.P.J., Dercksen, M.W., van de Wouw, A.J., Pepels, M.J.A.E., de Fallois, A.O.J., Lobbezoo, D.J.A., de Boer, M., Tjan-Heijnen, V.C.G.

“…We aimed to assess the implementation and effectiveness of exemestane plus everolimus treatment per hospital type in real-life, shortly after approval of…”
Get full text

The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia by Smilde, T J, van den Berkmortel, F W, Wollersheim, H, van Langen, H, Kastelein, J J, Stalenhoef, A F

“…Background Early in the process of atherosclerosis, changes in vessel wall stiffness and thickness may occur. The present study evaluates the effect of…”
Get full text

Associations between the Geriatric-8 and 4-meter gait speed test and subsequent delivery of adjuvant chemotherapy in older patients with colon cancer by Beukers, K., Bessems, S.A.M., van de Wouw, A.J., van den Berkmortel, F.W.P.J., Belgers, H.J., Konsten, J.L.M., Sipers, W.M.W.H., Janssen-Heijnen, M.L.G.

“…Feasible screening methods are important to identify older patients who might benefit from adjuvant chemotherapy. The aim of this study was to investigate the…”
Get full text

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? by Lobbezoo, D J A, van Kampen, R J W, Voogd, A C, Dercksen, M W, van den Berkmortel, F, Smilde, T J, van de Wouw, A J, Peters, F P J, van Riel, J M G H, Peters, N A J B, de Boer, M, Peer, P G M, Tjan-Heijnen, V C G

“…Background: We aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval,…”
Get full text

Progressive arterial wall stiffening in patients with increasing diastolic blood pressure by VAN DEN BERKMORTEL, F. W. P. J, VAN DER STEEN, M, HOOGENBOOM, H, WOLLERSHEIM, H, VAN LANGEN, H, THIEN, Th

“…Hypertension is an established risk factor for cardiovascular disease. Risk factor patterns for various cardiovascular complications are different. We studied…”
Get full text

In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium by Lobbezoo, D.J.A., van Kampen, R.J.W., Voogd, A.C., Dercksen, M.W., van den Berkmortel, F., Smilde, T.J., van de Wouw, A.J., Peters, F.P.J., van Riel, J.M.G.H., Peters, N.A.J.B., de Boer, M., Peer, P.G.M., Tjan-Heijnen, V.C.G.

“…The objective of this study was to present initial systemic treatment choices and the outcome of hormone receptor-positive (HR+) metastatic breast cancer. All…”
Get full text

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry by Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Bloem, M., Blokx, W.A.M., Boers-Sonderen, M.J., Bonenkamp, J.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Haanen, J.B., Holtslag, C.E., Hospers, G.A.P., Piersma, D., van Rijn, R.S., Stevense-den Boer, A.M., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Vreugdenhil, G., Wouters, M.W.J.M., Portielje, J.E.A., de Glas, N.A.

“…Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of…”
Get full text

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry by van Zeijl, M.C.T., de Wreede, L.C., van den Eertwegh, A.J.M., Wouters, M.W.J.M., Jochems, A., Schouwenburg, M.G., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., ten Tije, A.J., van der Veldt, A.A.M., Vreugdenhil, G., van der Hoeven, J.J.M., Haanen, J.B.A.G.

“…The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time…”
Get full text

Smoking or its cessation does not alter the susceptibility to in vitro LDL oxidation by Van Den Berkmortel, F. W. P. J., Demacker, P. N. M., Wollersheim, H., Thien, T., Stalenhoef, A. F. H.

“…Background Enhanced induction of low density lipoprotein (LDL) oxidation may play a role in the increased cardiovascular risk in smokers. We determined LDL…”
Get full text

Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study by Vernooij, R.W.M., Cremers, R.G.H.M., Jansen, H., Somford, D.M., Kiemeney, L.A., van Andel, G., Wijsman, B.P., Busstra, M.B., van Moorselaar, R.J.A., Wijnen, E.M., Pos, F.J., Hulshof, M.C.C.M., Hamberg, P., van den Berkmortel, F., Hulsbergen-van de Kaa, C.A., van Leenders, G.J.L.H., Fütterer, J.J., van Oort, I.M., Aben, K.K.H.

“…•Population-based studies on functional outcomes after prostate cancer treatment are scarce.•15% of prostatectomy patients reported urinary incontinence 24…”
Get full text

Corrigendum to “Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study” by Vernooij, R.W.M., Cremers, R.G.H.M., Jansen, H., Somford, D.M., Kiemeney, L.A., van Andel, G., Wijsman, B.P., Busstra, M.B., van Moorselaar, R.J.A., Wijnen, E.M., Pos, F.J., Hulshof, M.C.C.M., Hamberg, P., van den Berkmortel, F., Hulsbergen-van de Kaa, C.A., van Leenders, G.J.L.H., Fütterer, J.J., van Oort, I.M., Aben, K.K.H.

Get full text

Survival of stage IV melanoma in Belgium and the Netherlands by Suijkerbuijk, K.P.M., Haanen, J.B.A.G., Boers‐Sonderen, M.J., Hospers, G.A.P., Blank, C.U., den Berkmortel, F.W.P.J., Groot, J.W.B., Piersma, D., Aarts, M.J.B., Rijn, R.S., Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., Veldt, A.A.M., den Eertwegh, A.J.M.

Get full text

Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium by van Kampen, R.J.W, Ramaekers, B.L.T, Lobbezoo, D.J.A, de Boer, M, Dercksen, M.W, van den Berkmortel, F, Smilde, T.J, van de Wouw, A.J, Peters, F.P.J, van Riel, J.M.G, Peters, N.A.J.B, Tjan-Heijnen, V.C.G, Joore, M.A

“…Abstract Introduction The aim of our analysis was to assess the real-world cost-effectiveness of bevacizumab in addition to taxane treatment versus taxane…”
Get full text

Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma by Blom, R. L. G. M., Sosef, M. N., Nap, M., Lammering, G., van den Berkmortel, F., Hulshof, M. C. C. M., Meijer, S. L., Wilmink, H. W., van Berge Henegouwen, M. I.

“…Summary The implementation of neoadjuvant chemoradiotherapy (CRT) in esophageal cancer (EC) patients has led to improved survival rates. Worldwide, different…”
Get full text